News | December 31, 2019

Principia Updates PRN1008 Pemphigus Clinical Program Accelerated enrollment of company’s Phase 3 pivotal trial anticipating final results in second half of 2021 SOUTH SAN FRANCISCO, Calif., Dec. 30, 2019 (GLOBE NEWSWIRE) — Principia Biopharma Inc. (Nasdaq:...

News | December 16, 2019

Kit Check’s Bluesight for Controlled Substances Solution Implemented at 10 OhioHealth Hospitals Rapid cloud-based implementation for nationally recognized health system committed to addressing drug diversion and the opioid crisis already yielding results WASHINGTON...

News | December 9, 2019

Omnicell and Kit Check Partner to Offer Cloud-based Solution for Tracking of Controlled Substances Medication intelligence software solution supports critical need for hospitals and health systems to identify drug diversion to combat national opioid crisis MOUNTAIN...

News | December 6, 2019

MPI Label Systems Partners With Kit Check To Provide Custom RFID Tags for Medication Inventory Tracking Label leader engineers top RFID tags for pharmaceuticals, follows FDA guidelines for best labeling practice WASHINGTON (December 06, 2019) – Kit Check, the leader...

News | October 23, 2019

ARVINAS PRESENTS A PLATFORM UPDATE, INCLUDING INITIAL DATA FROM THE FIRST TWO CLINICAL TRIALS OF PROTAC® TARGETED PROTEIN DEGRADERS -Data from initial cohorts suggest that Arvinas’ PROTAC® platform has the potential to create safe and well-tolerated orally...

News | November 21, 2019

HARPOON THERAPEUTICS AND ABBVIE ANNOUNCE LICENSING AND OPTION COLLABORATION TO ADVANCE HPN217, HARPOON’S BCMA-TARGETING TRITAC®, AND EXPAND EXISTING DISCOVERY COLLABORATION Harpoon grants AbbVie option to license worldwide rights to HPN217 (BCMA), a TriTAC for the...